The Canadian nuclear reactor that satisfies more than half of demand of molybdenum-99 for medical nuclear imaging services in North America will not return to service until the first quarter of 2010.
The Canadian nuclear reactor that satisfies more than half of demand of molybdenum-99 for medical nuclear imaging services in North America will not return to service until the first quarter of 2010.
Atomic Energy Canada Limited announced Wednesday that it was rolling back the estimated startup date for the National Research Universal reactor at Chalk River, ON. The reactor was shut down May 14 after a heavy-water leak penetrating its vessel wall was discovered. AECL initially estimated repairs would be completed in late 2009.
The shutdown triggered a widespread shortage of Mo-99, the precursor isotope necessary for the production of technetium-99m, a radioisotope used in a majority of nuclear medicine procedures. Most nuclear medicine departments in the U.S. and Canada were affected. The situation worsened in June when the High Flux Reactor at Petten, the Netherlands, another important source of Mo-99 production, was shut down for planned routine maintenance.
Dr. Jean-Luc Urbain, chairman of nuclear medicine at the University of Western Ontario in London, told Diagnostic Imaging during an Aug. 4 interview that his department was receiving only 40% of its usual Mo-99 consignment. As with many facilities in Canada and the U.S., his clinic had delayed noncritical imaging procedures and shifted to thallium-201 for nuclear cardiology and FDG PET for cancer diagnosis and staging.
AECL rolled back its reactor startup date to Q1 2010 after a nondestructive survey of the containment vessel identified nine sites of corrosive wall-thinning requiring repair.
Safety-related problems at the NRU reactor have been the cause of two extended medical isotope shortages since 2007. The current incident triggered calls in the U.S. for Congress to approve funding to reestablish a domestic source of Mo-99. The last domestic provider ceased operations in 1989.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.